High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers

Background and purpose: High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III HER2-negative breast cancer with homologous recombination deficiency (HRD). In addition to survival, the impact on short- and lon...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Acta oncologica Ročník 63; číslo 1; s. 701 - 709
Hlavní autoři:	Verbeek, Joost G.E., Azarang, Leyla, Pilli, Luis E., De Jong, Vincent M.T., Jager, Agnes, Linn, Sabine C., Retèl, Valesca P., Van Harten, Wim H.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Sweden MJS Publishing on behalf of Acta Oncologica 10.09.2024 Medical Journals Sweden
Témata:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use BRCA1 Protein BRCA2 Protein Breast neoplasms Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Choice Behavior Conjoint Analysis Discrete Choice Experiment Female Health Personnel - psychology Homologous Recombination Humans Middle Aged Neoplasm Staging Original Receptor, ErbB-2 - metabolism
ISSN:	1651-226X, 0284-186X, 1651-226X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Background and purpose: High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III HER2-negative breast cancer with homologous recombination deficiency (HRD). In addition to survival, the impact on short- and long-term side effects might influence the uptake of HDCT by healthcare professionals. As part of the SUBITO trial, we investigated healthcare professionals’ treatment (outcome) preferences for patients with HRD stage III HER2-negative breast cancer and established how healthcare professionals make trade-offs between these treatment outcomes. Patients/material and methods: We conducted a discrete choice experiment in which healthcare professionals were asked to choose repeatedly between scenarios with two treatment options (HDCT or standard of care (SOC)) that varied in outcome with respect to 10-year overall survival (OS), short-term toxicity, long-term cognitive impairment, and premature menopause. We analysed treatment preferences, relative importance, and trade-offs using a multinomial logistic model. Results and interpretation: Thirty-five of the 151 dedicated breast cancer professionals with extensive experience in treating breast cancer patients completed the survey. The 10-year OS and long-term cognitive impairment were the most important attributes. The results indicate a requirement of 10.4% and 25.1% absolute additional improvement in the 10-year survival rate to justify accepting moderate or severe long-term cognitive impairment as a trade-off, respectively. Therefore, we found in our dataset that healthcare professionals expected a large improvement in 10-year OS to accept moderate to severe cognitive impairment. This information calls for further research into chemotherapy-related cognitive impairment, shared decision-making, and treatment preferences for patients with stage III breast cancer.
AbstractList	High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III HER2-negative breast cancer with homologous recombination deficiency (HRD). In addition to survival, the impact on short- and long-term side effects might influence the uptake of HDCT by healthcare professionals. As part of the SUBITO trial, we investigated healthcare professionals' treatment (outcome) preferences for patients with HRD stage III HER2-negative breast cancer and established how healthcare professionals make trade-offs between these treatment outcomes.BACKGROUND AND PURPOSEHigh-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III HER2-negative breast cancer with homologous recombination deficiency (HRD). In addition to survival, the impact on short- and long-term side effects might influence the uptake of HDCT by healthcare professionals. As part of the SUBITO trial, we investigated healthcare professionals' treatment (outcome) preferences for patients with HRD stage III HER2-negative breast cancer and established how healthcare professionals make trade-offs between these treatment outcomes.We conducted a discrete choice experiment in which healthcare professionals were asked to choose repeatedly between scenarios with two treatment options (HDCT or standard of care (SOC)) that varied in outcome with respect to 10-year overall survival (OS), short-term toxicity, long-term cognitive impairment, and premature menopause. We analysed treatment preferences, relative importance, and trade-offs using a multinomial logistic model.PATIENTS/MATERIAL AND METHODSWe conducted a discrete choice experiment in which healthcare professionals were asked to choose repeatedly between scenarios with two treatment options (HDCT or standard of care (SOC)) that varied in outcome with respect to 10-year overall survival (OS), short-term toxicity, long-term cognitive impairment, and premature menopause. We analysed treatment preferences, relative importance, and trade-offs using a multinomial logistic model.Thirty-five of the 151 dedicated breast cancer professionals with extensive experience in treating breast cancer patients completed the survey. The 10-year OS and long-term cognitive impairment were the most important attributes. The results indicate a requirement of 10.4% and 25.1% absolute additional improvement in the 10-year survival rate to justify accepting moderate or severe long-term cognitive impairment as a trade-off, respectively. Therefore, we found in our dataset that healthcare professionals expected a large improvement in 10-year OS to accept moderate to severe cognitive impairment. This information calls for further research into chemotherapy-related cognitive impairment, shared decision-making, and treatment preferences for patients with stage III breast cancer.RESULTS AND INTERPRETATIONThirty-five of the 151 dedicated breast cancer professionals with extensive experience in treating breast cancer patients completed the survey. The 10-year OS and long-term cognitive impairment were the most important attributes. The results indicate a requirement of 10.4% and 25.1% absolute additional improvement in the 10-year survival rate to justify accepting moderate or severe long-term cognitive impairment as a trade-off, respectively. Therefore, we found in our dataset that healthcare professionals expected a large improvement in 10-year OS to accept moderate to severe cognitive impairment. This information calls for further research into chemotherapy-related cognitive impairment, shared decision-making, and treatment preferences for patients with stage III breast cancer. High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III HER2-negative breast cancer with homologous recombination deficiency (HRD). In addition to survival, the impact on short- and long-term side effects might influence the uptake of HDCT by healthcare professionals. As part of the SUBITO trial, we investigated healthcare professionals' treatment (outcome) preferences for patients with HRD stage III HER2-negative breast cancer and established how healthcare professionals make trade-offs between these treatment outcomes. We conducted a discrete choice experiment in which healthcare professionals were asked to choose repeatedly between scenarios with two treatment options (HDCT or standard of care (SOC)) that varied in outcome with respect to 10-year overall survival (OS), short-term toxicity, long-term cognitive impairment, and premature menopause. We analysed treatment preferences, relative importance, and trade-offs using a multinomial logistic model. Thirty-five of the 151 dedicated breast cancer professionals with extensive experience in treating breast cancer patients completed the survey. The 10-year OS and long-term cognitive impairment were the most important attributes. The results indicate a requirement of 10.4% and 25.1% absolute additional improvement in the 10-year survival rate to justify accepting moderate or severe long-term cognitive impairment as a trade-off, respectively. Therefore, we found in our dataset that healthcare professionals expected a large improvement in 10-year OS to accept moderate to severe cognitive impairment. This information calls for further research into chemotherapy-related cognitive impairment, shared decision-making, and treatment preferences for patients with stage III breast cancer. Background and purpose: High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III HER2-negative breast cancer with homologous recombination deficiency (HRD). In addition to survival, the impact on short- and long-term side effects might influence the uptake of HDCT by healthcare professionals. As part of the SUBITO trial, we investigated healthcare professionals’ treatment (outcome) preferences for patients with HRD stage III HER2-negative breast cancer and established how healthcare professionals make trade-offs between these treatment outcomes. Patients/material and methods: We conducted a discrete choice experiment in which healthcare professionals were asked to choose repeatedly between scenarios with two treatment options (HDCT or standard of care (SOC)) that varied in outcome with respect to 10-year overall survival (OS), short-term toxicity, long-term cognitive impairment, and premature menopause. We analysed treatment preferences, relative importance, and trade-offs using a multinomial logistic model. Results and interpretation: Thirty-five of the 151 dedicated breast cancer professionals with extensive experience in treating breast cancer patients completed the survey. The 10-year OS and long-term cognitive impairment were the most important attributes. The results indicate a requirement of 10.4% and 25.1% absolute additional improvement in the 10-year survival rate to justify accepting moderate or severe long-term cognitive impairment as a trade-off, respectively. Therefore, we found in our dataset that healthcare professionals expected a large improvement in 10-year OS to accept moderate to severe cognitive impairment. This information calls for further research into chemotherapy-related cognitive impairment, shared decision-making, and treatment preferences for patients with stage III breast cancer.
Author	Jager, Agnes De Jong, Vincent M.T. Verbeek, Joost G.E. Azarang, Leyla Van Harten, Wim H. Linn, Sabine C. Retèl, Valesca P. Pilli, Luis E.
Author_xml	– sequence: 1 givenname: Joost G.E. orcidid: 0000-0001-6204-1877 surname: Verbeek fullname: Verbeek, Joost G.E. – sequence: 2 givenname: Leyla surname: Azarang fullname: Azarang, Leyla – sequence: 3 givenname: Luis E. surname: Pilli fullname: Pilli, Luis E. – sequence: 4 givenname: Vincent M.T. surname: De Jong fullname: De Jong, Vincent M.T. – sequence: 5 givenname: Agnes surname: Jager fullname: Jager, Agnes – sequence: 6 givenname: Sabine C. surname: Linn fullname: Linn, Sabine C. – sequence: 7 givenname: Valesca P. orcidid: 0000-0002-5624-3234 surname: Retèl fullname: Retèl, Valesca P. – sequence: 8 givenname: Wim H. surname: Van Harten fullname: Van Harten, Wim H.
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/39256991$$D View this record in MEDLINE/PubMed
BookMark	eNpVks1u1DAUhSNURH_gDRDyks1M_ZfEYYNQBXSkSmxAYmfdONeJqyQOtqdlXocnxdNpR-3Klu_xd3yvz3lxMvsZi-I9o2suJL1kVclWnFe_15xyuZaU19Wr4ux4fPJsf1qcx3hLKeWiLt8Up6LhZdU07Kz4d-36YdX5iMQMOPk0YIBlR6wPZIHkcE6R3Ls0kJigR7LZbEgbEGIiBmaD4VAc_ORH3_ttJAGNn1o358t-Jh1aZzLF7D4RIJ2LJmDae3lnkODfBYObsgmByc89GRDGNBgISJbg71yHIb4tXlsYI757XC-KX9--_ry6Xt38-L65-nKzMpLLtAJulbJUMNkooKBs3UDuva0kNZw3tmSqpJaC6VqsDavaUgqsO1pWSjQdl-Ki2By4nYdbveR3QdhpD04_HPjQawjJmRE1p5KrruGyLkFaVJnIJK8kqyy0vDaZ9fnAWrbthJ3JHQYYX0BfVmY36N7facYkbRRrMuHjIyH4P1uMSU95eDiOMGMesxaMcqWoEGWWfnhudnR5-uUskAeBCT7GgPYoYVTvw6T3SdH7pOh9mPRDmMR_w1vACA
Cites_doi	10.1146/annurev-publhealth-031912-114444 10.2105/AJPH.2008.146209 10.1016/j.jval.2016.04.004 10.1038/s41582-021-00617-2 10.1016/j.jval.2012.08.2223 10.1200/JCO.2007.11.2813 10.1016/j.jval.2022.01.012 10.1177/1534735420938450 10.1111/j.1742-1241.2010.02463.x 10.18637/jss.v095.i11 10.1186/s13012-017-0675-8 10.1158/1078-0432.CCR-14-1894 10.1093/annonc/mdz012 10.1002/hbm.21422 10.3747/co.19.1287 10.1016/j.psychres.2019.04.025 10.1002/ijc.30078 10.1038/nrc3342 10.1097/MLR.0b013e3182408812 10.1093/jnci/90.3.210 10.1017/S0266462309990882 10.1186/1748-5908-4-10 10.1007/978-1-4020-5753-3 10.2165/00019053-200826080-00004 10.1007/s40271-019-00375-w 10.1093/annonc/mdq624 10.1038/bjc.2013.370 10.1136/bmj.320.7248.1530 10.1080/23809000.2016.1139458 10.1016/j.jval.2010.11.013 10.1111/j.1524-4733.2009.00670.x 10.1038/clpt.2011.112 10.1186/s12885-022-10412-x 10.1016/j.vhri.2020.10.002 10.1186/1748-5908-9-69 10.1200/EDBK_389516 10.1177/2381468320928012
ContentType	Journal Article
Copyright	2024 The Author(s) 2024
Copyright_xml	– notice: 2024 The Author(s) 2024
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA
DOI	10.2340/1651-226X.2024.40276
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE CrossRef
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1651-226X
EndPage	709
ExternalDocumentID	oai_doaj_org_article_20428d92475a4fe8be71426416fab27c PMC11409819 39256991 10_2340_1651_226X_2024_40276
Genre	Journal Article
GroupedDBID	--- 00X 03L 23M 2WC 36B 4.4 5GY 5RE 6J9 AAFWJ AALUX AAWTL AAYXX ABDBF ABEIZ ABLIJ ABLJU ABLKL ABNNA ABUPF ABXYU ACCJX ACGEJ ACGFO ACGFS ACUHS ADBBV ADCVX ADRBQ ADXPE AECIN AEGXH AENEX AEOZL AFKVX AFPKN AGDLA AGYJP AIAGR AIJEM AJWEG AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU AQTUD BABNJ BAWUL BLEHA BOHLJ CCCUG CITATION COF CS3 DKSSO EAP EBB EBC EBD EBS EMB EMK EMOBN EPL ESX F5P GROUPED_DOAJ H13 HZ~ KRBQP KSSTO KWAYT KYCEM L7B LJTGL M4Z O9- OK1 P2P PGMZT RPM SV3 TDBHL TFDNU TFL TFW TUS UEQFS V1S WH7 ~1N 0BK ACENM AEXWM AGFJD ALYBC CGR CUY CVF DIK ECM EIF GX1 NPM TERGH 7X8 5PM
ID	FETCH-LOGICAL-c424t-a2f88f031498a0a8f79a226b640c229f51850f0acdbe7c16b543e7d056839d243
IEDL.DBID	DOA
ISICitedReferencesCount	0
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001410613200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1651-226X 0284-186X
IngestDate	Mon Nov 10 04:31:40 EST 2025 Tue Nov 04 02:04:59 EST 2025 Thu Jul 10 17:05:15 EDT 2025 Wed Feb 19 02:09:00 EST 2025 Sat Nov 29 07:33:54 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
License	https://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c424t-a2f88f031498a0a8f79a226b640c229f51850f0acdbe7c16b543e7d056839d243
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Shared last author Supplemental data for this article can be accessed online at https://doi.org/10.2340/1651-226X.2024.40276
ORCID	0000-0002-5624-3234 0000-0001-6204-1877
OpenAccessLink	https://doaj.org/article/20428d92475a4fe8be71426416fab27c
PMID	39256991
PQID	3102880335
PQPubID	23479
PageCount	9
ParticipantIDs	doaj_primary_oai_doaj_org_article_20428d92475a4fe8be71426416fab27c pubmedcentral_primary_oai_pubmedcentral_nih_gov_11409819 proquest_miscellaneous_3102880335 pubmed_primary_39256991 crossref_primary_10_2340_1651_226X_2024_40276
PublicationCentury	2000
PublicationDate	2024-09-10
PublicationDateYYYYMMDD	2024-09-10
PublicationDate_xml	– month: 09 year: 2024 text: 2024-09-10 day: 10
PublicationDecade	2020
PublicationPlace	Sweden
PublicationPlace_xml	– name: Sweden
PublicationTitle	Acta oncologica
PublicationTitleAlternate	Acta Oncol
PublicationYear	2024
Publisher	MJS Publishing on behalf of Acta Oncologica Medical Journals Sweden
Publisher_xml	– name: MJS Publishing on behalf of Acta Oncologica – name: Medical Journals Sweden
References	75329 75328 75327 75326 75369 75402 75368 75401 75367 75400 75366 75365 75364 75363 75362 75361 75360 75339 75338 75337 75336 75335 75379 75334 75378 75333 75377 75332 75376 75331 75375 75330 75374 75373 75372 75370 cr-split#-75371.1 cr-split#-75371.2 75349 75348 75347 75346 75345 75389 75344 75388 75343 75387 75342 75386 75341 75385 75340 75384 75383 75382 75381 75380 75359 75358 75357 75356 75355 75399 75354 75398 75353 75397 75352 75396 75351 75395 75350 75394 75393 75392 75391 75390
References_xml	– ident: 75344 doi: 10.1146/annurev-publhealth-031912-114444 – ident: 75378 – ident: 75349 doi: 10.2105/AJPH.2008.146209 – ident: 75381 doi: 10.1016/j.jval.2016.04.004 – ident: 75367 doi: 10.1038/s41582-021-00617-2 – ident: 75375 doi: 10.1016/j.jval.2012.08.2223 – ident: 75389 doi: 10.1200/JCO.2007.11.2813 – ident: 75400 doi: 10.1016/j.jval.2022.01.012 – ident: 75390 doi: 10.1200/JCO.2007.11.2813 – ident: 75396 doi: 10.1177/1534735420938450 – ident: 75359 doi: 10.1111/j.1742-1241.2010.02463.x – ident: 75377 doi: 10.18637/jss.v095.i11 – ident: 75342 doi: 10.1186/s13012-017-0675-8 – ident: 75329 doi: 10.1158/1078-0432.CCR-14-1894 – ident: 75373 doi: 10.1093/annonc/mdz012 – ident: 75393 doi: 10.1002/hbm.21422 – ident: 75357 doi: 10.3747/co.19.1287 – ident: 75338 doi: 10.1016/j.psychres.2019.04.025 – ident: 75330 doi: 10.1002/ijc.30078 – ident: #cr-split#-75371.2 – ident: 75333 doi: 10.1038/nrc3342 – ident: 75328 doi: 10.1158/1078-0432.CCR-14-1894 – ident: 75348 doi: 10.2105/AJPH.2008.146209 – ident: 75340 doi: 10.1097/MLR.0b013e3182408812 – ident: 75332 doi: 10.1038/nrc3342 – ident: 75392 doi: 10.1093/jnci/90.3.210 – ident: 75341 – ident: 75358 doi: 10.1111/j.1742-1241.2010.02463.x – ident: 75399 doi: 10.1016/j.jval.2022.01.012 – ident: 75335 doi: 10.1017/S0266462309990882 – ident: 75368 doi: 10.1038/s41582-021-00617-2 – ident: 75372 – ident: 75334 – ident: 75353 doi: 10.1186/1748-5908-4-10 – ident: 75337 doi: 10.1016/j.psychres.2019.04.025 – ident: 75376 doi: 10.18637/jss.v095.i11 – ident: 75366 doi: 10.1007/978-1-4020-5753-3 – ident: 75391 doi: 10.1093/jnci/90.3.210 – ident: #cr-split#-75371.1 – ident: 75347 doi: 10.2165/00019053-200826080-00004 – ident: 75384 doi: 10.1007/s40271-019-00375-w – ident: 75326 doi: 10.1093/annonc/mdq624 – ident: 75354 doi: 10.1038/bjc.2013.370 – ident: 75365 doi: 10.1136/bmj.320.7248.1530 – ident: 75369 doi: 10.1080/23809000.2016.1139458 – ident: 75356 doi: 10.3747/co.19.1287 – ident: 75363 doi: 10.1016/j.jval.2010.11.013 – ident: 75374 doi: 10.1093/annonc/mdz012 – ident: 75380 doi: 10.1111/j.1524-4733.2009.00670.x – ident: 75343 doi: 10.1186/s13012-017-0675-8 – ident: 75345 doi: 10.1146/annurev-publhealth-031912-114444 – ident: 75398 doi: 10.1038/clpt.2011.112 – ident: 75370 doi: 10.1080/23809000.2016.1139458 – ident: 75360 doi: 10.1186/s12885-022-10412-x – ident: 75388 doi: 10.1016/j.vhri.2020.10.002 – ident: 75336 doi: 10.1017/S0266462309990882 – ident: 75382 doi: 10.1016/j.jval.2016.04.004 – ident: 75350 doi: 10.1186/1748-5908-9-69 – ident: 75364 doi: 10.1136/bmj.320.7248.1530 – ident: 75401 doi: 10.1200/EDBK_389516 – ident: 75346 doi: 10.2165/00019053-200826080-00004 – ident: 75397 doi: 10.1038/clpt.2011.112 – ident: 75402 doi: 10.1200/EDBK_389516 – ident: 75352 doi: 10.1186/1748-5908-4-10 – ident: 75355 doi: 10.1038/bjc.2013.370 – ident: 75395 doi: 10.1177/1534735420938450 – ident: 75386 doi: 10.1177/2381468320928012 – ident: 75361 doi: 10.1186/s12885-022-10412-x – ident: 75383 doi: 10.1007/s40271-019-00375-w – ident: 75331 doi: 10.1002/ijc.30078 – ident: 75327 doi: 10.1093/annonc/mdq624 – ident: 75351 doi: 10.1186/1748-5908-9-69 – ident: 75379 doi: 10.1111/j.1524-4733.2009.00670.x – ident: 75362 doi: 10.1016/j.jval.2010.11.013 – ident: 75394 doi: 10.1002/hbm.21422 – ident: 75385 doi: 10.1177/2381468320928012 – ident: 75339 doi: 10.1097/MLR.0b013e3182408812 – ident: 75387 doi: 10.1016/j.vhri.2020.10.002
SSID	ssj0002375
Score	2.4091463
Snippet	Background and purpose: High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients... High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III...
SourceID	doaj pubmedcentral proquest pubmed crossref
SourceType	Open Website Open Access Repository Aggregation Database Index Database
StartPage	701
SubjectTerms	Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use BRCA1 Protein BRCA2 Protein Breast neoplasms Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Choice Behavior Conjoint Analysis Discrete Choice Experiment Female Health Personnel - psychology Homologous Recombination Humans Middle Aged Neoplasm Staging Original Receptor, ErbB-2 - metabolism
Title	High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers
URI	https://www.ncbi.nlm.nih.gov/pubmed/39256991 https://www.proquest.com/docview/3102880335 https://pubmed.ncbi.nlm.nih.gov/PMC11409819 https://doaj.org/article/20428d92475a4fe8be71426416fab27c
Volume	63
WOSCitedRecordID	wos001410613200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1651-226X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002375 issn: 1651-226X databaseCode: DOA dateStart: 20240101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAWR databaseName: Taylor & Francis Journals Complete customDbUrl: eissn: 1651-226X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002375 issn: 1651-226X databaseCode: TFW dateStart: 19870101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nj9MwEB3BCiEuK74JLCsjcQ04_ohtbiyiohKsOCyiN8txHLqHJqjprsTf4Zcyk6SlRUhcuORQV4rlNxm_l8w8A7wsXFVhGFBZuZUoUJTLra5SrqxW0ZoahwbL_I_m_NwuFu7z3lFfVBM22gOPC4fiHAlyjSrB6KCaZKtkCtrFi7IJlTCRsi83biumphwspNFjo5yQir8uSl3kSDQWKAiFeoWaiTxG9jaiwa__byTzz1rJvc1ndheOJ9bI3o6zvQc3Unsfbn-avos_gJ9UrpHXXZ8YgrCauqp-MGSkbHJO7Rm9cmVIBr8lNp_PWUXl6BsWCfb1OLjsVpQLu6uekVBeoWoegGN1IqMJ6tJ8wwKjTt41km28V4d5hv0-JYANZxex5a6ojG07_fqH8GX2_uLdh3w6fSGPSqhNHkRjbUPu9s4GHmxjXMAlrErFoxCu0bjT84aHWCMksSgrrWQyNRIq5Fy1UPIRHLVdm54Aw6QgZWgELxupdEzWBUe2-iapWHLhMsi3UPjvo8mGR3FC0HmCzhN0nqDzA3QZnBFeu_-SRfbwAwaOnwLH_ytwMnixRdvjI0XfSUKbcIW9JNJluZQ6g8cj-rtbIZ3UJXLqDOxBXBzM5XCkvVwOtt0FeYshAXv6P2b_DO7QelDlSsFP4GizvkrP4Va83lz261O4aRb2dHgk8Hox-_oLwQQQkQ
linkProvider	Directory of Open Access Journals
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High-dose+chemotherapy+for+patients+with+stage+III+breast+cancer+with+homologous+recombination+deficiency%3A+a+discrete+choice+experiment+among+healthcare+providers&rft.jtitle=Acta+oncologica&rft.au=Verbeek%2C+Joost+G.E.&rft.au=Azarang%2C+Leyla&rft.au=Pilli%2C+Luis+E.&rft.au=De+Jong%2C+Vincent+M.T.&rft.date=2024-09-10&rft.issn=1651-226X&rft.eissn=1651-226X&rft.volume=63&rft.spage=701&rft.epage=709&rft_id=info:doi/10.2340%2F1651-226X.2024.40276&rft.externalDBID=n%2Fa&rft.externalDocID=10_2340_1651_226X_2024_40276
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1651-226X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1651-226X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1651-226X&client=summon